Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

JAK2 -mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms

Blood (2019) 134 (21): 1832–1846.

https://doi.org/10.1182/blood.2019000162

Published: 2019

Includes: Supplemental data

Journal Articles

Targeting Cell Non-Autonomous MAPK Activation As a Novel Therapeutic Strategy in Myeloproliferative Neoplasms

Sara C. Meyer, MD PhD, Nilabh Ghosh, MSc, Simona Stivala, PhD, Anne Baerenwaldt, PhD, Hui Hao-Shen, Stefan Dirnhofer, MD, Matthias S. Dettmer, MD, Cédric Simillion, PhD, Sophia Chiu, MSc, Matthew Keller, MSc, Maria Kleppe, PhD, Morgane Hilpert, PhD, Andreas S. Buser, MD, Jakob R. Passweg, MDMS, Thomas Radimerski, PhD, Radek C. Skoda, MD, Ross L. Levine, MD

Blood (2017) 130 (Supplement 1): 381.

https://doi.org/10.1182/blood.V130.Suppl_1.381.381

Published: 2017

Journal Articles

Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia

Blood (2017) 129 (11): e26–e37.

https://doi.org/10.1182/blood-2016-09-738070

Published: 2017

Includes: Supplemental data

Journal Articles

JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis

Jean Grisouard, Sai Li, Lucia Kubovcakova, Tata Nageswara Rao, Sara C. Meyer, Pontus Lundberg, Hui Hao-Shen, Vincent Romanet, Masato Murakami, Thomas Radimerski, Stephan Dirnhofer, Radek C. Skoda

Blood (2016) 128 (6): 839–851.

https://doi.org/10.1182/blood-2015-12-689216

Published: 2016

Includes: Supplemental data

Journal Articles

Drug Response Profiling to Identify Selective Pharmacological Activity in Drug Resistant ALL

Viktoras Frismantas, MSc, Maria Pamela Dobay, PhD, Anna Rinaldi, PhD, Kunz Joachim, MD, Blerim Marovca, Peter Horvath, PhD, Mauro Delorenzi, PhD, Gunnar Cario, MD, Martin Schrappe, MD, Martin Stanulla, MD, Andreas E. Kulozik, MD PhD, Martina U. Muckenthaler, PhD, Arend Stackelberg, MD, Cornelia Eckert, Thomas Radimerski, PhD, Beat Bornhauser, PhD, Jean-Pierre Bourquin, MD PhD

Blood (2015) 126 (23): 2532.

https://doi.org/10.1182/blood.V126.23.2532.2532

Published: 2015

Journal Articles

Type II Inhibition of JAK2 with NVP-CHZ868 Reverses Type I JAK Inhibitor Persistence and Demonstrates Increased Efficacy in MPN Models

Sara C Meyer, MD PhD, Matthew D Keller, BS, Priya Koppikar, PhD, Olga A Guryanova, MD PhD, Maria Kleppe, PhD, Anna Sophia McKenney, MPH, William R Sellers, MD, Francesco Hofmann, PhD, Fabienne Baffert, Christoph Gaul, PhD, Thomas Radimerski, PhD, Ross L Levine, MD

Blood (2014) 124 (21): 160.

https://doi.org/10.1182/blood.V124.21.160.160

Published: 2014

Journal Articles

Type II JAK2 Inhibitor NVP-CHZ868 Is Active in Vivo Against JAK2-Dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs)

Blood (2014) 124 (21): 3713.

https://doi.org/10.1182/blood.V124.21.3713.3713

Published: 2014

Journal Articles

The Combination Of JAK Inhibitor, Ruxolitinib, and PIM Inhibitor, LGH447, In Preclinical Models Of Myeloproliferative Neoplasia

Abdel Saci, Ph.D., Maria Pinzon-Ortiz, Dannie Wang, Xianhui Rong, Joseph Growney, Ph.D., Margaret Squier, MD, PhD, Thomas Radimerski, PhD, K. Gary Vanasse, Giordano Caponigro, Pablo D Garcia, PhD, Z. Alexander Cao

Blood (2013) 122 (21): 4100.

https://doi.org/10.1182/blood.V122.21.4100.4100

Published: 2013

Journal Articles

JAK2 L884P Mutation Confers Resistance To The Type II JAK2 Inhibitor NVP-BBT594 When Co-Occurring With JAK2 R683G But Not JAK2 V617F

Nadja Kopp, Jordy C. Van der Zwet, Jacob Layer, Oliver Weigert, Eric Vangrevelinghe, Akinori Yoda, PhD, Thomas Radimerski, PhD, David Weinstock, MD

Blood (2013) 122 (21): 1429.

https://doi.org/10.1182/blood.V122.21.1429.1429

Published: 2013

Journal Articles

Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2 -V617F polycythemia vera mouse model

Lucia Kubovcakova, Pontus Lundberg, Jean Grisouard, Hui Hao-Shen, Vincent Romanet, Rita Andraos, Masato Murakami, Stephan Dirnhofer, Kay-Uwe Wagner, Thomas Radimerski, Radek C. Skoda

Blood (2013) 121 (7): 1188–1199.

https://doi.org/10.1182/blood-2012-03-415646

Published: 2013

Includes: Supplemental data

Journal Articles

Improved Efficacy Upon Combined JAK1/2 and Pan-Deacetylase Inhibition Using Ruxolitinib (INC424) and Panobinostat (LBH589) in Preclinical Mouse Models of JAK2 V617F-Driven Disease

Fabienne Baffert, Emeline Evrot, M.S., Nicolas Ebel, M.S., Claudia Roelli, Rita Andraos, M.S., Zhiyan Qian, M.S., Vincent Romanet, MSc, Masato Murakami, MD, PhD, Thomas Radimerski, PhD

Blood (2011) 118 (21): 798.

https://doi.org/10.1182/blood.V118.21.798.798

Published: 2011

Journal Articles

HSP90 Inhibition Targets JAK2 and Is Highly Effective in CRLF2-Rearranged Acute Lymphoblastic Leukemia

Oliver Weigert, MD, Liat Bird, Nadja Kopp, Andrew A. Lane, MD, PhD, Bjoern Chapuy, MD, PhD, Diederik van Bodegom, Sachie Marubayashi, Akinori Yoda, PhD, Vincent Romanet, MSc, Masato Murakami, MD, PhD, Stephen E. Sallan, MD, Ross L Levine, MD, Andrew L. Kung, MD, PhD, Thomas Radimerski, PhD, David M Weinstock, MD

Blood (2011) 118 (21): 576.

https://doi.org/10.1182/blood.V118.21.576.576

Published: 2011

Journal Articles

Genetic Resistance to JAK2 Enzymatic Inhibitors Is Overcome by HSP90 Inhibition

Oliver Weigert, MD, Andrew A. Lane, MD, PhD, Liat Bird, Nadja Kopp, Angela V Toms, Ph.D., Christoph Gaul, Eric Vangrevelinghe, Alain De Pover, Catherine H. Regnier, PhD, Dirk Erdmann, Francesco Hofmann, PhD, Michael Eck, Andrew L. Kung, MD, PhD, Thomas Radimerski, PhD, David M Weinstock, MD

Blood (2011) 118 (21): 62.

https://doi.org/10.1182/blood.V118.21.62.62

Published: 2011

Journal Articles

Novel, Potent and Selective JAK2 Inhibitors.

Blood (2009) 114 (22): 3777.

https://doi.org/10.1182/blood.V114.22.3777.3777

Published: 2009

NARROW

JAK2 -mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms

Targeting Cell Non-Autonomous MAPK Activation As a Novel Therapeutic Strategy in Myeloproliferative Neoplasms

Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia

JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis

Drug Response Profiling to Identify Selective Pharmacological Activity in Drug Resistant ALL

Type II Inhibition of JAK2 with NVP-CHZ868 Reverses Type I JAK Inhibitor Persistence and Demonstrates Increased Efficacy in MPN Models

Type II JAK2 Inhibitor NVP-CHZ868 Is Active in Vivo Against JAK2-Dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs)

The Combination Of JAK Inhibitor, Ruxolitinib, and PIM Inhibitor, LGH447, In Preclinical Models Of Myeloproliferative Neoplasia

JAK2 L884P Mutation Confers Resistance To The Type II JAK2 Inhibitor NVP-BBT594 When Co-Occurring With JAK2 R683G But Not JAK2 V617F

Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2 -V617F polycythemia vera mouse model

Improved Efficacy Upon Combined JAK1/2 and Pan-Deacetylase Inhibition Using Ruxolitinib (INC424) and Panobinostat (LBH589) in Preclinical Mouse Models of JAK2 V617F-Driven Disease

HSP90 Inhibition Targets JAK2 and Is Highly Effective in CRLF2-Rearranged Acute Lymphoblastic Leukemia

Genetic Resistance to JAK2 Enzymatic Inhibitors Is Overcome by HSP90 Inhibition

Novel, Potent and Selective JAK2 Inhibitors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only